Physician profile
Julia Freling
NPI 1386030302
$475.43
in general payments reported to CMS, 2019-2025
13 companies · $21.20 in 2025
The $21.20 reported for 2025 was less than what a typical Obstetrics provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.66 · 2020: $13.74 · 2021: $34.34 · 2022: $289 · 2023: $89.58 · 2025: $21.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $110.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $185.08 | 2019-2023 | |
| Coopersurgical, INC. | $59.30 | 2019-2023 | Summit Doppler |
| Organon LLC | $54.61 | 2022-2025 | |
| Therapeuticsmd, INC. | $27.10 | 2022 | |
| Sumitomo Pharma America, INC. | $22.59 | 2023 | Myfembree |
| Sage Therapeutics, LLC | $20.72 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $18.35 | 2022 | |
| Pfizer INC. | $16.33 | 2022 | |
| Agile Therapeutics, INC. | $16.31 | 2023 | Twirla |
| Meditrina | $15.58 | 2023 | |
| Exeltis, USA INC. | $14.52 | 2022 | |
| Evofem Biosciences, INC. | $12.53 | 2022 | |
| Ascend Therapeutics US, LLC | $12.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Freling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.